40 results about "Incretin" patented technology

The present disclosure relates to a method of preventing or treating a disease or disorder in a subject in need thereof, wherein administration of a composition of the present disclosure is effective to result in an increase of energy expenditure in the subject. The present disclosure provides a method of reducing fat mass and / or improving glycemic control in a subject in need thereof. The present disclosure provides a method of promoting weight loss and weight maintenance. The present disclosure provides a method of maintaining lean mass. Compositions for use in the methods include a compound of formula (I), (II), or (III), or pharmaceutically acceptable salts thereof, or in combination with a compound selected from the group consisting of an ACC2 inhibitor and an incretin mimetic.

A computer implemented method for determining a dosage of semaglutide for administering to a patient for the treatment of obesity includes receiving patient data relating to a patient, wherein the patient data includes patient weight data; processing the patient data with a dosage calculator to determine the dosage of semaglutide for administering to the patient; and administering the dosage.

Provided herein are incretin analog compounds that are GLP-1 / GIP / Gcg receptor triple agonists and their medical use in the treatment and / or prevention of a disease such as dyslipidemia, fatty liver disease, metabolic syndrome, MASH, MAFLD, obesity and T2DM.

Doses and dosing regimens for incretin analogs are disclosed comprising determining and administering doses of long-acting incretin analogs suitable for once-weekly dosing, such as a glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) (GGG) tri-receptor agonist.

The present invention provides a method for treating obesity or an obesity-related disease or disorder, comprising administering a PYY analog in combination with an incretin, wherein the patient's insulin sensitivity is improved with treatment.

The invention discloses preparation and application of a corn polypeptide with functions of inhibiting amyloglucosidase activity and promoting GLP-1 secretion, and belongs to the technical field of functional food. And the corn polypeptide is PYPR, PPAPR and PLRP (Poly Lactic Polymerase Chain Reaction). The corn polypeptide is obtained by enzymolysis of corn protein through alkaline protease, and is novel in structure and easy to prepare. The corn polypeptide can inhibit the activity of amyloglucosidase in vitro, can significantly promote GLP-1 secretion, and can up-regulate the expression of gcg and gc3 genes related to GLP-1 synthesis and a polypeptide recognition receptor GPR93 by regulating Ca < 2 + > influx and an ATP signal channel, thereby improving the steady state of blood glucose. The invention provides reference for developing functional food or health care products with the functions of reducing blood sugar and promoting secretion of insulin.

Orally administered pharmaceutical compositions comprising incretin or its analogues or derivatives are presented, which allow for prolonged glycemic control. The formulations presented herein incorporate a self-emulsifying drug delivery system (SEDDS). Advantageously, such formulations provide protection in the upper gastrointestinal tract from proteolytic conditions while allowing for efficient drug release and absorption in the lower gastrointestinal tract.

Doses and dosing regimens for incretin analogs are disclosed comprising determining and administering doses of long-acting incretin analogs suitable for once-weekly dosing, such as a glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) (GGG) tri-receptor agonist.

To provide apparatuses and methods for stimulating L cells of the small intestine to produce incretins and other peptides for treatment of various diseases and conditions including diabetes and obesity.SOLUTION: Embodiments of the invention provide apparatuses and methods for stimulating L cells in the intestinal tract to produce incretins for treatment of conditions including diabetes and obesity. Many embodiments provide a method and apparatus for treatment of diabetes by electrically stimulating L cells for secretion of incretins, so as to stimulate or otherwise modulate production of insulin. Particular embodiments provide a swallowable capsule for stimulating L cells in the intestinal tract as the capsule moves through the tract.SELECTED DRAWING: Figure 4

Disclosed are compounds that are parathyroid hormone receptor 1 agonists, and methods useful for preventing or treating osteoporosis, fracture, osteomalacia, arthritis, thrombocytopenia, hypoparathyroidism, hyperphosphatemia or tumoral calcinosis. Also disclosed are agonists of GLP-1R, GCGR, and / or GIPR, and methods of treating various therapeutic indications by administering an effective amount of an agonist of GLP-1R, GCGR, and / or GIPR.

Disclosed are compounds that are parathyroid hormone receptor 1 agonists, and methods useful for preventing or treating osteoporosis, fracture, osteomalacia, arthritis, thrombocytopenia, hypoparathyroidism, hyperphosphatemia or tumoral calcinosis. Also disclosed are agonists of GLP-1R, GCGR, and / or GIPR, and methods of treating various therapeutic indications by administering an effective amount of an agonist of GLP-1R, GCGR, and / or GIPR.

The present invention provides methods and compositions for preventing, reducing, or treating adverse effects caused by an incretin agonist or antagonist containing weight loss drug or a sodium-glucose transport protein 2 (SGLT-2) inhibitor in a subject who is under treatment or stops treatment with the incretin agonist or antagonist containing weight loss drug or SGLT-2 inhibitor. The method comprises co-administering or administering after discontinuation of the incretin agonist or antagonist containing weight loss drug or SGLT-2 inhibitor to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound represented by a structure of Formulas I, II, VIII, IX, X, XI, XII, XIII, and XIV disclosed herein to the subject under incretin agonist or antagonist containing drug or SGLT-2 agent therapy.

It relates to incretin analog compounds that are GLP-1 / GIP / GCG receptor triple agonists and their medical use in the treatment and / or prevention of a disease such as dyslipidemia, fatty liver disease, metabolic syndrome, MASH, obesity and T2DM.

The present invention relates to the field of treatment for body composition changes in weight management. In some embodiments, the present invention provides compositions and methods for mitigating the adverse effects of treatment by weight loss drugs that suppress appetite including incretin agonist or antagonist containing drugs such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) or by sodium-glucose transport protein 2 (SGLT-2) inhibitors.

Doses and dosing regimens for incretin analogs are disclosed comprising determining and administering doses of long-acting incretin analogs suitable for once-weekly dosing, such as a glucagon-like peptide-1 (GLP-1) and glucagon (Gcg) co-agonist.

Methods of treating metabolic disorders are disclosed herein, wherein the methods administer combinations of a sodium / glucose co- transporter 1 (SGLT1) inhibitor with a glucagon-like peptide agonist 1 (GLP 1), a gastric inhibitory peptide- 1 (GIP-1) analog, and / or d) a dual GLP-1-GIP-l receptor agonist.

Disclosed herein are methods of treating metabolic disorders, wherein the method administers a combination of a sodium / glucose co-transporter 1 (SGLT1) inhibitor and a glucagon-like peptide agonist 1 (GLP 1), a Gastrosuppressive Peptide-1 (GIP-1) analog, and / or d) a dual GLP-1-GIP-1 receptor agonist.

The present disclosure relates to isolated oligopeptides capable of activating glucagon-like peptide (GLP) receptors, as well as formulations of the oligopeptides. The formulations are suitable for improving glycemic control and reducing excess body weight of overweight individuals.

A computer implemented method for determining a dosage of Cagrisema for administering to a patient for the treatment of obesity, the method comprising: receiving patient data relating to a patient, wherein the patient data includes patient weight data; processing the patient data including the patient weight data with a dosage calculator to determine the dosage of Cagrisema for administering to the patient wherein the dosage calculator is derived from a pharmacokinetic, PK, model; and indicating the dosage.

Compositions are provided that include an incretin analog having activity at each of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG) receptors (i.e., avian receptor agonists) and one or more additional agents, such as a tonicity agent and a preservative. Methods are also provided for treating diseases, such as type 2 diabetes, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and obesity, with the compositions.

Incretin analogs are provided that have activity at each of the GIP, GLP-1 and glucagon receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as diabetes mellitus, dyslipidemia, fatty liver disease, metabolic syndrome, non-alcoholic steatohepatitis and obesity.

This disclosure provides GLP-1 / GIP and GLP-1 / GCG dual receptor agonists comprising incretin analog polypeptides, as well as their use in the treatment or prevention of type 2 diabetes mellitus (T2DM), hyperlipidemia / dyslipidemia, metabolic syndrome, metabolic dysfunction-related fatty liver disease (MASLD), metabolic dysfunction-related steatohepatitis (MASH), neurodegenerative disorders, fibrosis, cardiovascular risk, and / or obesity.

A method for improving the solubility of a pharmaceutical compound is disclosed, wherein the pharmaceutical compound is insulin, a natural insulin variant, an insulin variant or insulin analog, a GLP-1 agonist, a GIP agonist, a glucagon agonist, an amylin agonist or an incretin mimic. The method involves using a non-nutritive sugar, such as raspberry glycoside, neohesperidin A, dulcitin B, dodecyl-β-D-maltodextrin (DDM), or carhariside, or any combination thereof, in the presence of a solvent such as ethanol or a mixture thereof, followed by removal of the solvent by drying and re-solubilization to generate a water-soluble complex. The complex formed using the disclosed method is also described.

Incretin analogs are provided that have activity at each of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as type 2 diabetes mellitus, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and obesity.

A computer implemented method for determining a dosage of semaglutide for administering to a patient for the treatment of obesity includes receiving patient data relating to a patient, wherein the patient data includes patient weight data; processing the patient data with a dosage calculator to determine the dosage of semaglutide for administering to the patient; and administering the dosage.

Disclosed are compounds that are parathyroid hormone receptor 1 agonists, and methods useful for preventing or treating osteoporosis, fracture, osteomalacia, arthritis, thrombocytopenia, hypoparathyroidism, hyperphosphatemia or tumoral calcinosis. Also disclosed are agonists of GLP-1R, GCGR, and / or GIPR, and methods of treating various therapeutic indications by administering an effective amount of an agonist of GLP-1R, GCGR, and / or GIPR.

The subject matter of the present disclosure generally relates to techniques for neuromodulation that include applying energy (e.g., ultrasound energy) into the tissue to cause a change in a glucose transporter pathway molecule and / or an incretin pathway molecule. In one embodiment, the neuromodulation is performed as a treatment of a metabolic disorder.

Disclosed are compounds that are parathyroid hormone receptor 1 agonists, and methods useful for preventing or treating osteoporosis, fracture, osteomalacia, arthritis, thrombocytopenia, hypoparathyroidism, hyperphosphatemia or tumoral calcinosis. Also disclosed are agonists of GLP-1R, GCGR, and / or GIPR, and methods of treating various therapeutic indications by administering an effective amount of an agonist of GLP-1R, GCGR, and / or GIPR.

The present invention relates to methods for incremental weight loss and to the field of treatment to improve body composition changes and physical function with weight reduction. In some embodiments, the present invention provides compositions and methods for mitigating the adverse effects of treatment by weight loss drugs that suppress appetite including incretin agonist or antagonist containing drugs such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs), GIP, glucagon, amylin, or by sodium-glucose transport protein 2 (SGLT-2) inhibitors.

The present invention relates to the field of treatment for body composition changes in weight management. In some embodiments, the present invention provides compositions and methods for mitigating the adverse effects of treatment by weight loss drugs that suppress appetite including incretin agonist or antagonist containing drugs such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) or by sodium-glucose transport protein 2 (SGLT-2) inhibitors. In one embodiment, the present invention provides a composition of semaglutide and a selective androgen receptor modulator (SARM) compound of Formula IX.